TABLE 1.
Antigens for peptide‐based therapeutic cancer vaccines
| Tumour | Tumour‐specific antigens | Tumour‐associated antigens |
|---|---|---|
| Glioma | EphA2, HSD3B7, Neuritin, TTK | |
| Squamous cell carcinoma of head and neck | EBV‐LMP, HPV | |
| Oesophageal cancer | URLC10 | CEA, HSP105, KOC1,TTK, VEGFR |
| Lung cancer | CDCA1, KIF20A, Lengsin, MAGE‐A, NY‐ESO‐1, PRAME, URLC10 | CDC45L, CEA, HER2, IDO, KOC1, MUC1, SOX2, STEAP1, Survivin, TERT, TTK, VEGFR |
| Breast cancer | PLAC1, CDCA1, E6/E7a (HPV), URLC10, KIF20A, m‐P53 | CEA, DEPDC1, ErbB2, FBP, HER2/neu, Mam‐A, MPHOSPHl, MUC1, TAL6,TTK |
| Malignant pleural mesothelioma | MUC1 | |
| Liver cancer | AFP, Cyclophilin B, GPC3, HNRPL, HPSE, p56Lck, ppMAPkkk, SART3, Survivin, UBE2V, VEGFR, WHSC2 | |
| Cholangiocarcinoma | KIF20A, MAGE‐A, m‐P53 | β‐catenin, CEA, DEPDC1, EpCAM, EZH2, GPC3, HER2/neu, IMP3, LY6K, MRP3, MUC5AC, SART1, Survivin, TTK, WT1 |
| Pancreatic cancer | KIF20A | CEA, Survivin, VEGFR |
| Gastric cancer | MCAK, URLC10, FoxM1 | CEA, Survivin, VEGFR, KOC1 |
| Bladder cancer | MPHOSPH1, DEPDC1 | |
| Prostatic cancer | CDCA1, PSMA, SSX‐2, TARP | CD44, EpCAM, AR LBD, KLK4, PSCA, HPN |
| Renal carcinoma | PRAME | 5T4, 7RGS5, ADFP, APOL, CCND1, FGF‐5, GUCY1A3, HIG2, ITGA3, KIAA036, MET, MUC1, Survivin, telomerase |
| Osteosarcoma | PBF | |
| Melanoma | MAGE‐A, NY‐ESO‐1, PRAME, E7a (HPV) | gp100, MART‐1, Melan‐A, NA17, Survivin, TBVA, telomerase, Tyrosinase, VEGFR |
| Cervical carcinoma | E6/E7a (HPV) | Survivin |
| Ovarian cancer | m‐P53 | CEA, ErbB2, FBP, FR, GPC3, HER2/neu, Mesothelin, MUC1, WT1 |
| Leukaemia | PRAME, m‐p53 | CG, PR3, Survivin, telomerase, WT1 |
| Colorectal cancer | MCAK, E6/E7a (HPV) | AGR2, CEA, HERV‐H, HPSE, HSP105, MTA1, RNF43, Survivin, TOMM34, VEGFR |
| Lymphoma | MAGE‐A, SSX‐2 | EBNA1, Survivin, XBP1, CD138 |